Santarus,
SNTS and VeroScience, LLC today announced that new
analyses of cardiovascular endpoint data from a previously disclosed
52-week, randomized safety study with CYCLOSET®
(bromocriptine mesylate) tablets were published in the Journal of the
American Heart Association (JAHA), an online publication. CYCLOSET
is a unique, quick release form of bromocriptine, a dopamine D2 receptor
agonist, and is approved as an adjunct to diet and exercise to improve
glycemic control in adults with type 2 diabetes mellitus.
In this safety study, a total of 3,070 patients on stable doses of up to
two antidiabetes medications (including insulin) with HbA1c ≤ 10.0
(average baseline HbA1c=7.0) were randomized 2:1 to CYCLOSET (1.6 to
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in